Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

MMRF to Speed Development of Targeted Therapies

November 5, 2014 10:31 am | News | Comments

The Multiple Myeloma Research Foundation announced an initiative designed to accelerate the evaluation of new investigational therapies for multiple myeloma. Read more...               

TOPICS:

GSK Submits European, US Filings for Asthma Med

November 5, 2014 10:14 am | News | Comments

GlaxoSmithKline announced that it has filed regulatory submissions in the USA and Europe for mepolizumab for approval as a maintenance treatment for patients with severe eosinophilic asthma. Read more...          

TOPICS:

Scientists Create Prostate Cancer Drug-Testing Tool

November 5, 2014 9:48 am | News | Comments

Scientists at Bath have developed an innovative tool to test potential drugs for prostate cancer. Read more...                         

TOPICS:
Advertisement

BRCA-Targeting Drugs Could Treat Prostate Cancer

November 5, 2014 9:31 am | News | Comments

A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer. Read more...               

TOPICS:

WHO's Next Africa Chief is Elected

November 5, 2014 9:03 am | News | Comments

World Health Organization elected its next Africa director, a doctor from Botswana who is a longtime veteran of the U.N. agency at a meeting in Benin. Read more...                

TOPICS:

Google's Next Business Venture: The Human Body

November 4, 2014 2:07 pm | by Ryan Bushey, Associate Editor | Articles | Comments

Google is working on a slew of ambitious projects that could drastically revolutionize healthcare as we know it. Read more...                       

TOPICS:

Amgen's Trebananib Fails to Improve Survival in Phase 3 Ovarian Cancer Study

November 4, 2014 1:36 pm | News | Comments

Amgen announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. Read more...              

TOPICS:

FDA Study Reaffirms Safety and Efficacy Profile of Pradaxa

November 4, 2014 1:23 pm | News | Comments

An FDA study of more than 134,000 Medicare patients found that Pradaxa was associated with significantly reduced risks of ischemic stroke and intracranial hemorrhage and death. Read more...           

TOPICS:
Advertisement

Startup's Technology Could Improve Cancer Drug Development

November 4, 2014 12:59 pm | News | Comments

Officials at a life sciences startup based on a Purdue University innovation said their technology could help pharmaceutical companies find more effective drug candidates and improve the results of personalized cancer care. Read more...    

TOPICS:

Immunotherapy for Cancer Toxic with Obesity

November 4, 2014 11:51 am | News | Comments

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found. Read more...                 

TOPICS:

Dana-Farber, Astellas Collaborate on Cancer Research

November 4, 2014 10:44 am | News | Comments

Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer. Read more...

TOPICS:

AstraZeneca, Janssen Partner on Immunocology Trials

November 4, 2014 10:38 am | News | Comments

AstraZeneca  and Janssen have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Imbruvica(ibrutinib), an oral Bruton's tyrosine kinase inhibitor. Read more...

TOPICS:

Abide Collaborates With Oxford on Drug Targets

November 4, 2014 10:30 am | News | Comments

Abide Therapeutics announced that the company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets.  Read more...

TOPICS:

Identifying New Drugs to Treat Lyme Disease

November 4, 2014 10:24 am | News | Comments

Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a test they say will allow them to test thousands of FDA-approved drugs to see if they will work against the bacteria that causes tick-borne Lyme disease. Read more...

TOPICS:

Using Real-World Data for Outcomes Research and Comparative Effectiveness Studies

November 4, 2014 10:17 am | by Christina Mack, Ph.D., MSPH, Associate Director, Epidemiology, Real-World & Late Phase Research, Quintiles, and Kathy Lang, Ph.D., Senior Director, Emerging Businesses Data & Analytics, Real-World & Late Phase Research, Quintiles | Articles | Comments

Biopharma is increasingly harnessing the power of data collected outside of a controlled clinical environment to generate valuable insights to support products throughout their lifecycle. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading